BTK and B-cell chronic lymphocytic leukemia: The covalent BTK inhibitor orelabrutinib was approved in China for relapsed/refractory chronic lymphocytic leukemia, small lymphocytic lymphoma, and relapsed/refractory mantle cell lymphoma and, after having received breakthrough designation for cancer treatment with the FDA this year, could be another candidate for indication expansion into the autoimmune space.